ADAP Advocacy Unveils Survey on Long-Acting Injectables for HIV Prevention

Survey Seeks Patient Perspectives from People Who are HIV-Negative on Long-Acting Injectables HIV Pre-Exposure Prevention

For Immediate Release: Media Contact:
February 1, 2024 info@adapadvocacy.org

WASHINGTON, D.C. – ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, launched an online survey to gain better patient perspectives from people who are HIV-negative about approved LAI medications for HIV Pre-Exposure Prophylaxis (PrEP). The online survey is open to people who are HIV-Negative and residing in the United States and its Territories.

LAIs are prescription medications designed to either prevent the transmission of HIV or treat HIV over an extended period. These medications can be used to replace daily oral medications. However, anecdotal evidence suggests that access barriers remain.

“Obstacles and operational barriers to timely access of new agents, including HIV pre-exposure injectables, have increased with the advent of newer injectable therapies,” summarized Riley Johnson, Project Manager of the ADAP Advocacy’s Long-Acting Injectables Project. “The barriers that commonly occur hinder equitable access for HIV-negative people who are seeking Injectable PrEP, regardless of their health insurance status. Our survey provides patients not living with HIV an opportunity to share their experiences trying to access this prevention tool.”

The U.S. Food & Drug Administration (FDA) recently approved the first long-acting injectable for use in at-risk adults and adolescents for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. ViiV Healthcare’s Apretude (cabotegravir extended-release injectable suspension) is the first LAI on the market for HIV prevention.


ADAP Advocacy’s Long-Acting Injectables Project is made possible with support from Gilead Sciences, Merck, and ViiV Healthcare.

To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or its Long-Acting Injectables Project, please email info@adapadvocacy.org.

####

About ADAP Advocacy: ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.